BioCentury | Dec 8, 2014
Clinical News

Subcutaneous veltuzumab regulatory update

...FDA granted Orphan Drug designation to subcutaneous veltuzumab to treat pemphigus. The humanized anti-CD20 antibody has completed...
...to out-license the compound. Immunomedics Inc. (NASDAQ:IMMU), Morris Plains, N.J. Product: Subcutaneous veltuzumab ( hA20 , IMMU-106...
BioCentury | Oct 14, 2013
Company News

Immunomedics, Takeda deal

...Immunomedics said Takeda terminated a 2008 deal and returned to Immunomedics rights to subcutaneous veltuzumab , a...
...proceedings in September to settle its allegations that delays by Takeda's Nycomed unit in developing veltuzumab...
...arbitration for damages. In 2008, Immunomedics granted Nycomed exclusive, worldwide rights to develop and commercialize subcutaneous veltuzumab...
BioCentury | Oct 14, 2013
Finance

Highlights of weekly biotech stock moves

...week after Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) terminated a 2008 deal and returned rights to subcutaneous veltuzumab...
...development of veltuzumab. In May, Nycomed said it was planning a Phase II trial of veltuzumab...
BioCentury | Oct 9, 2013
Company News

Takeda returns veltuzumab to Immunomedics

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) terminated a 2008 deal and returned to Immunomedics rights to subcutaneous veltuzumab...
...started arbitration proceedings to settle its allegations that delays by Takeda's Nycomed unit in developing veltuzumab...
...arbitration for damages. In 2008, Immunomedics granted Nycomed exclusive, worldwide rights to develop and commercialize subcutaneous veltuzumab...
BioCentury | Sep 26, 2013
Cover Story

Anti-CD20 therapy for heart attack

...Humanized mAb Phase III for MS Immunomedics Inc. (NASDAQ:IMMU)/Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) Veltuzumab (hA20; IMMU-106...
BioCentury | Jun 17, 2013
Clinical News

Epratuzumab-Rap: Interim Phase I/II data

...portion of an open-label, U.S. Phase I/II trial showed that weekly 200 mg/m 2 IV veltuzumab-RAP...
...partial responses. The trial is enrolling patients with NHL who failed >=1 prior standard regimen. Veltuzumab-RAP...
BioCentury | Jun 17, 2013
Clinical News

Veltuzumab-Rap: Interim Phase I/II data

...portion of an open-label, U.S. Phase I/II trial showed that weekly 200 mg/m 2 IV veltuzumab-RAP...
...Nuclear Medicine and Molecular Imaging meeting in Vancouver. Immunomedics Inc. (NASDAQ:IMMU), Morris Plains, N.J. Product: Veltuzumab-Rap...
BioCentury | Jun 10, 2013
Product Development

O-ver and above

...include two Type I antibodies: TG Therapeutics Inc. 's glycoengineered ublituximab and Immunomedics Inc. 's veltuzumab...
BioCentury | May 20, 2013
Company News

Immunomedics, Takeda deal

...for the period ended March 31 that Takeda's Nycomed company will pursue clinical development of subcutaneous veltuzumab...
...believe that the SLE market has fewer therapeutic options, which offers greater commercial potential for veltuzumab...
...a humanized anti-CD20 antibody. Nycomed has exclusive, worldwide rights from Immunomedics to develop and commercialize subcutaneous veltuzumab...
BioCentury | Jan 14, 2013
Clinical News

Veltuzumab: Interim Phase I/II data

...Interim data from 42 evaluable patients in a Phase I/II trial showed that subcutaneous veltuzumab produced an...
...defined as platelet levels >=100,000/µL. In patients who have had ITP for <=1 year (n=12), subcutaneous veltuzumab...
...Morris Plains, N.J. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Veltuzumab ( hA20 , IMMU-106...
Items per page:
1 - 10 of 45